- Trial phase
- Phase 1
- Time to market
- At least several years away. The drug is in Phase 1 dose escalation (estimated primary completion March 2028), requiring Phase 2/3 trials and regulatory review before any potential approval.
- Why 5/10
- The next hard catalyst is the initial Phase 1 monotherapy dose escalation data presentation at the ASH Annual Meeting (Dec 12-15, 2026), about 6 weeks away. However, this is early-stage Phase 1 data (safety, tolerability, PK, preliminary efficacy), not a registrational readout or PDUFA decision, and ARV-393 is one of several pipeline programs at a company that also has an approved product (vepdegestrant).
The next hard catalyst is the initial Phase 1 monotherapy dose escalation data for ARV-393, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Positive safety and early efficacy signals could re-rate the stock from near its 52-week low; any safety or tolerability concerns would be a setback for the BCL6 degrader program. A second data readout is expected in mid-2027.
Price Chart
Executive Summary
ARV-393 (zaloblideg) is Arvinas's investigational oral PROTAC BCL6 degrader in Phase 1 testing for relapsed/refractory non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). It is one of the first clinical-stage BCL6 degraders, competing with BMS-986458 from Bristol Myers Squibb. The Phase 1 trial (NCT06393738, ~255 patients, recruiting) evaluates ARV-393 as monotherapy and in combination with glofitamab. The next major catalyst is the initial Phase 1 monotherapy dose escalation data, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Arvinas has $558.9M cash (runway into H2 2028) and an approved product (vepdegestrant/VEPPANU) that was out-licensed to Rigel. The stock trades near its 52-week low at $7.09 with analyst consensus leaning bullish (13 Buy/Strong Buy, mean PT $14.54).
How It Works
ARV-393 is an oral drug that uses Arvinas's PROTAC platform to hijack the cell's own garbage-disposal system (the proteasome) to specifically destroy the BCL6 protein. BCL6 is a master-switch protein that many lymphoma cells depend on to survive and grow. By eliminating BCL6 rather than just blocking it, the drug aims to kill cancer cells that have historically been difficult to treat with conventional approaches.
Trial Status
ARV-393 is being evaluated in a global, multicenter, open-label, first-in-human Phase 1 dose escalation and optimization/expansion study (NCT06393738) in patients with relapsed/refractory NHL. The trial includes monotherapy cohorts and a combination cohort with glofitamab in DLBCL. Enrollment is ongoing across 21 sites in 5 countries. Initial Phase 1 monotherapy dose escalation data has been submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026), with a second data readout expected in mid-2027.
The Two-Sided Case
Upcoming Catalysts
- Initial Phase 1 monotherapy dose escalation data presentation at ASH Annual Meeting (Dec 12-15, 2026)
- Second ARV-393 data readout expected mid-2027
- Potential initiation of glofitamab combination cohort in DLBCL
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arvinas Inc. PRESS-RELEASE ARVN ·Originating report